Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effects of rosiglitazone on bone in postmenopausal diabetic women

Trial Profile

Effects of rosiglitazone on bone in postmenopausal diabetic women

Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Jan 2011

At a glance

  • Drugs Rosiglitazone (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 06 Jan 2011 Two-year follow-up results have been published (Clinical Endocrinology 73:305-312, 01 Sep 2010)
    • 21 Sep 2007 Results reported at EASD 2007.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top